SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Hackers stole data from 4.5 million patients Data security breaches are a big issue in U.S.

GE Healthcare Life Sciences moves to Massachusetts $21-million-dollar facility to open in the spring

New imaging system monitors treatment in real time Improves quality of life and life span for cystic fibrosis patients

People want dementia diagnosed despite no cure New GE research shows worldwide consensus

ECRI founder and emeritus president passes away Dr. Joel Nobel dies at 79

Technique improves treatment of Alzheimer's and Parkinson's Uses acoustic pressure from ultrasound

Siemens' new CT algorithm gets FDA nod Improves reconstructed image quality

NorthStar will supply GE with Mo-99 Only U.S. domestic supply

Home infusion pump market is set to grow Expected to reach $26.7 billion by 2020

Intel and MJFF team up for Parkinson's disease Leveraging wearable devices and big data

Budget sequestration could impact FDA device reviews

by Loren Bonner , DOTmed News Online Editor
Medical device approval processes could be severely impacted due to automatic, across-the-board spending cuts set for March 1.

According to analysts at the health care consulting firm Avalere Health, so-called sequestration would deprive the agency of critical resources needed for the timely review of important medical products. Sequestration would cut 8.2 percent from the federal budget unless Congress and the White House can agree on a way to cut spending through other means like tax reform.

Story Continues Below Advertisement

FDA approved successor to the PRISM 3000 XP:

MultiCam 3000eco opens new financial and diagnostic opportunities. Inter Medical of Germany and Eclipse Systems offer the most effective triple-head gamma camera on the market for heart and brain diagnostics.



"If you go whack the FDA budget there will be layoffs," Dan Mendelson, CEO of Avalere, told DOTmed News. "It's just the only way they can survive relative to a highly labor intensive environment."

For example, clinical trials for devices, which require FDA approval, could be impacted if the FDA lacks the resources to let the manufacturers know that the trial is unsafe and should not proceed.

"By statute, the FDA has to let them [manufacturers] know in 30 days to stop and fix something before going forward," said Lakshman Ramamurthy, director FDA regulatory policy at Avalere. "If no one is there because of confusion, then the trial will proceed because they haven't been told to stop." Post-review processes could be equally impacted, according to Ramamurthy.

In addition, sequestration sets up a rare situation for the agency where increased user fees for 2013 are collected but not available to the agency.

In 2013, new user fee rates went into effect and as a result, the FDA agreed to hire more people.

"It's ironic because all the user fee payments will continue unabated but the agency will not be able to access that money so it sets up this world where the life sciences companies have to pay but the agency does not benefit," said Mendelson.

The problem is further exacerbated by the fact that FDA appropriations for fiscal year 2013 are set at 2012 funding levels.

While the FDA will have to make its own plans in the event they face budget cuts, Avalere officials hope the FDA is prepared for what may come on March 1.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED